From the Research
Mabthera (rituximab) and Ozempic (semaglutide) should not be used together without careful medical supervision due to their different mechanisms of action and potential side effects. Mabthera is a monoclonal antibody primarily used to treat certain types of cancer (like non-Hodgkin's lymphoma and chronic lymphocytic leukemia) and autoimmune conditions such as rheumatoid arthritis, as seen in a study comparing the efficacy and safety of the biosimilar Truxima and the originator MabThera in multiple sclerosis patients 1. It works by targeting and destroying B cells that have CD20 markers on their surface. Ozempic, on the other hand, is a GLP-1 receptor agonist used for managing type 2 diabetes and, more recently, for weight management, with a safety profile that includes mostly mild-to-moderate and transient gastrointestinal disturbances and an increased risk of biliary disease (cholelithiasis) 2. These medications have different mechanisms of action and side effect profiles, and their use together could lead to serious health complications, such as those associated with lymphoma in patients with rheumatoid arthritis 3, 4, 5. If you're currently taking one or both of these medications, or considering their use, it's essential to consult with your healthcare provider about your specific medical needs, potential drug interactions, and appropriate dosing schedules. Some key points to consider when using these medications include:
- The potential for increased risk of lymphoma in patients with rheumatoid arthritis treated with Mabthera 3, 4, 5
- The safety profile of Ozempic, including the risk of gastrointestinal disturbances and biliary disease 2
- The importance of careful medical supervision when using these medications together to minimize the risk of serious health complications.